NCT01814826已完成1 期
A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 8
- 主要终点
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in treatment naive participants with AML who were 60 years of age or older.
研究设计
- 研究类型
- Interventional
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with world health organization (WHO)-defined AML, 60 years of age or older, who are unlikely to benefit from standard induction therapy, defined as having at least 1 of the following:
- •Greater than or equal to 75 years of age.
- •Antecedent hematologic disease.
- •Known adverse cytogenetic risk.
- •Eastern Cooperative Oncology Group (ECOG) PS =
- •Participant must not have received definitive treatment for AML, defined as any prior chemotherapy with antileukemic activity.
- •ECOG PS 0 to
- •Expected survival longer than 3 months from enrollment in the study.
- •Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence.
- •Male participants who agree to practice effective barrier contraception or agree to practice true abstinence.
- •Voluntary written consent must be given before performance of any study-related procedure.
- •Suitable venous access for the study-required blood sampling.
- •Clinical laboratory values as specified below within 3 days before the first dose of any study drug:
- •Total bilirubin must be less than or equal to (<=) the upper limit of the normal range (ULN).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be<=2.5*ULN.
- •Serum creatinine <=1.5*ULN.
- •Albumin greater than or equal to (>=) 27 grams per liter (g/L).
- •Hemoglobin >9 grams per deciliter (g/dL). Note: It was permissible to transfuse participants with red blood cells to achieve this criterion.
- •White blood cell (WBC) count less than (<) 50,000 per microliter (/mcL) before administration of pevonedistat on Days 1, 3, and 5 of Cycle
- •Note: Hydroxyurea could be used to control the level of circulating leukemic blast cell counts to no lower than 10,000/mcL while on pevonedistat.
- •Able to undergo bone marrow aspiration and biopsy at screening.
排除标准
- •Previous treatment with azacitidine or decitabine.
- •Known favorable cytogenetic risk.
- •Any serious medical or psychiatric illness.
- •Treatment with any investigational products.
- •Known hypersensitivity to azacitidine or mannitol.
- •Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
- •Active uncontrolled infection or severe infectious disease.
- •Major surgery within 14 days before the first dose of study drug.
- •Life-threatening illness unrelated to cancer.
- •Clinically uncontrolled central nervous system (CNS) involvement.
- •WBC count greater than (>) 50,000/ mcL.
- •Prothrombin time (PT) or activated partial thromboplastin time (aPTT) >1.5* ULN or a history of coagulopathy or bleeding disorder
- •Known human immunodeficiency virus (HIV) positive.
- •Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
- •Known hepatic cirrhosis or severe pre-existing hepatic impairment.
- •Known cardiac/cardiopulmonary disease defined as 1 of the following:
- •Uncontrolled high blood pressure (that is, systolic blood pressure >180 milliliter per mercury (mm Hg), diastolic blood pressure >95 mm Hg).
- •Congestive heart failure New York Heart Association (NYHA) Class III or IV, or Class II with a recent decompensation that required hospitalization or referral to a heart failure clinic within 4 weeks before screening (see Section 15.4 of the protocol in Appendix 16.1.1).
- •Cardiomyopathy or history of ischemic heart disease
- •Participants with ischemic heart disease who had acute coronary syndrome (ACS), myocardial infarction (MI), and/or revascularization (example, coronary artery bypass graft, stent) in the past 6 months were excluded. However, participants with ischemic heart disease who had ACS, MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms could be enrolled.
- •Arrhythmia (example, history of polymorphic ventricular fibrillation or torsade de pointes). However, participants with <Grade 3 atrial fibrillation (a fib) for a period of at least 6 months could enroll. Grade 3 a fib is symptomatic and incompletely controlled medically, or controlled with device (example, pacemaker), or ablation. Participants with paroxysmal a fib were permitted to enroll.
- •Implantable cardioverter defibrillator.
- •Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing).
- •Pulmonary arterial hypertension. Prolonged rate corrected QT (QTc) interval >= 500 msec, calculated according to institutional guidelines
- •Left ventricular ejection fraction
- •Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis.
- •Body mass index >40 kilogram per square meter (kg/m^2).
- •Treatment with CYP3A inducers within 14 days before the first dose of MLN
- •Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of study drug, except for hydroxyurea.
研究组 & 干预措施
MLN4924 and Azacitidine
Experimental
干预措施: MLN4924 (Drug)
MLN4924 and Azacitidine
Experimental
干预措施: Azacitidine (Drug)
结局指标
主要结局
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
时间窗: Baseline up to 30 days after the last dose of study drug (up to 5 years)
Number of Participants With TEAEs Related to Clinically Significant Laboratory Evaluation Findings
时间窗: Baseline up to 30 days after the last dose of study drug (up to 5 years)
Number of Participants With TEAEs Related to Clinically Significant Vital Sign Findings
时间窗: Baseline up to 30 days after the last dose of study drug (up to 5 years)
次要结局
- Dose-escalation Phase, Cmax: Maximum Observed Plasma Concentration for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length is equal to [=] 28 days))
- Maximum Tolerated Dose (MTD) Expansion Phase, Cmax: Maximum Observed Plasma Concentration for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, Ctrough: Observed Plasma Concentration at the End of the Dosing Interval for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, Ctrough: Observed Plasma Concentration at the End of the Dosing Interval for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, AUC0-tau: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (Tau) for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, AUC0-tau: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (Tau) for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, AUC24hours: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-Dose for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, AUC24hours: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-Dose for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 24 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, AUCinf: Area Under the Plasma Concentration-time Curve Extrapolated to Infinity for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, AUCinf: Area Under the Plasma Concentration-time Curve Extrapolated to Infinity for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, Lambdaz: Terminal Disposition Phase Rate Constant for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, Lambdaz: Terminal Disposition Phase Rate Constant for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, t1/2: Terminal Disposition Phase Half-life for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, t1/2: Terminal Disposition Phase Half-life for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, Rac: Observed Accumulation Ratio for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, Rac: Observed Accumulation Ratio for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, CLp: Systemic Clearance for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, CLp: Systemic Clearance for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Dose-escalation Phase, Vss: Volume of Distribution at Steady-state for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- MTD Expansion Phase, Vss: Volume of Distribution at Steady-state for MLN4924(Cycle 1 Day 1 pre-dose and at multiple time points (up to 24 hours) post-dose; Cycle 1 Day 5 pre-dose and at multiple time points (up to 48 hours) post-dose (Cycle length = 28 days))
- Best Overall Response Rate(Cycle(C)1Day(D)22 and at C2 between D20 and 28 and at C4 and beyond C4 after completion of every 3rd C between D15 and 28 up to 30 days after last dose of study drug/before start of subsequent antineoplastic therapy, if that occurred sooner(up to 5 years))
- Duration of Response(From the date of first documented CR, PR or CRi up to the date of first disease progression (Up to 5 years))
- Overall Survival(From the first dose of study drug up to date of death (up to 5 years))
- Thirty-day Mortality Rate(30 days after the first dose of study drug in Cycle 1 (Cycle Length=28 days))
- Sixty-day Mortality Rate(60 days after the first dose of study drug on Cycle 1 (Cycle Length=28 days))
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid TumorsTumorsNCT00422682Sanofi136
终止
1 期
Dose Escalation of IPI-493 in Hematologic MalignanciesHematologic MalignanciesNCT01193491Infinity Pharmaceuticals, Inc.4
已完成
1 期
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsSolid TumorsNCT01862328Millennium Pharmaceuticals, Inc.64
已完成
1 期
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT01383928Millennium Pharmaceuticals, Inc.64
终止
1 期
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast CancerBreast CancerNCT03983395Ichnos Sciences SA1